微质反应部分调解了Aβ对阿尔茨海默病认知的影响
Lasse S Madsen1, Rola Ismail2, Peter Parbo3
1Department of Clinical Medicine, Center of Functionally Integrative Neuroscience, Aarhus University, Aarhus, Denmark.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|October 11, 2024
概括
在阿尔茨海默病中,粉样β (Aβ) 和微质反应独立地损害认知. 随着时间的推移,微质反应部分调解了Aβ对认知功能的负面影响.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 微质激活是阿尔茨海默病 (AD) 病理学的关键组成部分,与粉样β (Aβ) 积累密切相关.
- 研究Aβ,微质反应和认知衰退之间的相互作用对于理解AD进展至关重要.
研究的目的:
- 检查粉样β (Aβ) 沉积和微质反应对轻度认知障碍患者的全球认知障碍的纵向影响.
- 为了确定微质反应是否调解了Aβ负载和认知衰退之间的关系,在2年的时间内.
主要方法:
- 长度研究涉及28名轻度认知障碍患者和11名健康对照.
- 使用11C-PK11195和11C-匹兹堡化合物B的正子发射断层扫描 (PET),结构MRI和基线和2年随访的认知评估.
- 统计分析评估了PET吸收,认知评级和微质反应对Aβ认知关联的调解效应之间的相关性.
主要成果:
- 粉样β (Aβ) 负载和微质反应都与基线全球认知表现较差独立相关.
- 在2年的随访中,Aβ负载和全球认知之间的关联部分是由微质反应介导的.
- 这表明了一种动态的相互作用,其中微质活动影响了Aβ如何随着时间的推移影响认知.
结论:
- 随着阿尔茨海默病的进展,微质反应在调解粉样β (Aβ) 对认知的神经毒性作用方面发挥着重要作用.
- 这些发现强调了微质反应作为缓解AD认知衰退的潜在治疗标.
- 这项研究强调了在Aβ病理学背景下考虑神经炎症对于理解和治疗阿尔茨海默病的重要性.
相关概念视频
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Alzheimer's Disease: Treatment
166
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
166


